Obesity is a BMI-stratified chronic disease: 41.9% of US adults meet the threshold, 9.2% have severe obesity, and the comorbidity-defined subsegments, not the headline count, determine who gets covered.
Obesity is a chronic, relapsing metabolic disease defined by a body-mass index of 30 or greater. CDC NHANES data (2017–March 2020) put US adult obesity prevalence at 41.9%, approximately 100 million adults, with severe obesity (BMI ≥40) at 9.2%, roughly 22 million adults. The most recent NHANES cycle (August 2021–August 2023) shows age-adjusted obesity at 40.3% and severe obesity at 9.7%. Prevalence has climbed from 30.5% in 1999–2000, and severe obesity has doubled from 4.7%. The disease stratifies by BMI class: Class I (30–34.9), Class II (35–39.9), and Class III/severe (≥40), each carrying a different comorbidity load and a different treatment and coverage rationale.
The clinical case for treatment now rests on outcomes, not weight alone. Two GLP-1-based agents dominate: semaglutide 2.4mg (Wegovy, Novo Nordisk) delivered 15.3% weight loss in STEP 1, and tirzepatide (Zepbound, Eli Lilly) delivered 20.9% at its 15mg dose in SURMOUNT-1 — a clear head-to-head efficacy gap. Critically, the SELECT trial showed semaglutide cut major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes, converting obesity from a cosmetic indication into a cardiovascular one. That evidence reframes the addressable population around comorbidity-defined segments: obesity plus established CVD, obesity plus type 2 diabetes, which are precisely the segments payers and Medicare will fund.
US obesity by BMI class and comorbidity segment — prevalence and commercial implication
| Segment | US Prevalence / Size | Defining Feature | Clinical & Commercial Implication |
|---|---|---|---|
| All obesity (BMI ≥30) | 41.9% of adults · ~100M · NHANES 2017–Mar 2020 | BMI ≥30; total diagnosed pool | Full pharmacologically addressable base; commercial coverage gated by comorbidity |
| Class I–II obesity (BMI 30–39.9) | ~32.7% of adults · obesity minus severe (NHANES 2017–Mar 2020) | BMI 30–39.9; majority of the obese pool | GLP-1 first-line where comorbidity present; PA typically requires ≥1 comorbidity or BMI ≥35 |
| Severe obesity (Class III, BMI ≥40) | 9.2% of adults · ~22M · NHANES 2017–Mar 2020 | BMI ≥40; highest comorbidity and surgical load | Highest pharmacologic and bariatric priority; strongest coverage case |
| Obesity + established CVD | Subset of the obese pool (SELECT-eligible) | BMI ≥27 + prior MI/stroke/PAD, no diabetes | Wegovy CV indication population; the segment that opened Medicare Part D coverage |
| Obesity + type 2 diabetes | Overlapping metabolic segment | Co-existing type 2 diabetes | Separate GLP-1 T2D coverage pathway (Ozempic/Mounjaro); distinct reimbursement |
Sources: CDC NHANES / NCHS Data Brief No. 508 (obesity and severe-obesity prevalence, 2017–March 2020 and 2021–2023); NEJM STEP 1 (PMID 33567185); NEJM SURMOUNT-1 (PMID 35658024); NEJM SELECT (PMID 37952131).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • BMI-class distribution (Class I/II/III) and severe-obesity sizing • Comorbidity-defined segments: obesity + CVD (SELECT-eligible), obesity + type 2 diabetes • Addressable-population funnel from diagnosed to treatment-eligible • Prevalence trend and trajectory across NHANES cycles
Delivers
- • Weight-loss benchmarks: tirzepatide (SURMOUNT-1) vs semaglutide (STEP 1) • SELECT cardiovascular outcome data and the CVD-comorbidity segment • Efficacy by BMI class and comorbidity profile • Implications for line-of-therapy and switching
Delivers
- • Sizing logic for the obesity + established-CVD segment • Obesity–type 2 diabetes overlap and its separate coverage pathway • Why comorbidity, not BMI alone, governs the reimbursable population • Commercial micro-segmentation for targeting
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- The BMI-based classification (Class I 30-34.9, Class II 35-39.9, Class III/severe >=40) that stratifies obesity's comorbidity load
- Why each BMI class carries a distinct treatment and coverage rationale rather than a uniform obesity definition
- The rise from 30.5% obesity prevalence in 1999-2000 to 41.9% (2017-March 2020) and 40.3% in the most recent NHANES cycle (2021-2023)
- Severe obesity's climb from 4.7% to 9.7%, effectively doubling across the same NHANES tracking period
- The roughly 100 million US adults with BMI >=30 and the 22 million with severe obesity (BMI >=40)
- Why Class III/severe obesity carries the highest comorbidity and bariatric-surgical load, and the strongest coverage case
- How the SELECT trial's 20% MACE reduction converted obesity from a cosmetic indication into a cardiovascular one
- The distinct obesity-plus-CVD and obesity-plus-type-2-diabetes segments that anchor payer and Medicare coverage decisions
- Tirzepatide's 20.9% weight loss at 15mg (SURMOUNT-1) versus semaglutide's 15.3% (STEP 1), the class's head-to-head efficacy gap
- How these weight-loss benchmarks map onto BMI-class and comorbidity-based patient segmentation
- The comorbidity-defined segments (obesity plus established CVD and obesity plus type 2 diabetes) that payers actually fund
- Why BMI alone no longer determines the reimbursable population, comorbidity does
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and official public-health surveillance data — not secondary summaries. No market research reports or unverified estimates are used. Findings are independently verified before inclusion.
US Obesity Disease Landscape sources: CDC NHANES / NCHS Data Brief No. 508 (adult obesity and severe-obesity prevalence, 2017–March 2020 and August 2021–August 2023), and primary trial publications in the New England Journal of Medicine — STEP 1 (semaglutide; PMID 33567185), SURMOUNT-1 (tirzepatide; PMID 35658024), and SELECT (cardiovascular outcomes; PMID 37952131).
- US adult obesity prevalence (41.9%, 2017–March 2020) and severe obesity (9.2%) verified against CDC NHANES / NCHS Data Brief No. 508
- Tirzepatide 20.9% weight loss at 15mg verified against NEJM SURMOUNT-1 (PMID 35658024)
- Semaglutide 15.3% weight loss verified against NEJM STEP 1 (PMID 33567185)
- SELECT 20% MACE reduction (HR 0.80) verified against NEJM SELECT primary publication (PMID 37952131)
Frequently asked questions
Commission this assessment
AXLRx US Obesity Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US obesity population and its addressable subsegments. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.